Build Your Comparison

Side-by-side financial analysis
TIL logo
TIL
TMO logo
TMO
ILMN logo
ILMN
DHR logo
DHR
A logo
A
KO logo
KO
JPM logo
JPM
Try popular comparisons:

Stock Comparison

TIL vs TMO vs ILMN vs DHR vs A vs KO vs JPM

Revenue, margins, valuation, and 5-year total return — side by side.

Live fundamentals10-year financials5-year price chart
TIL
Instil Bio, Inc.

Biotechnology

HealthcareNASDAQ • US
Market Cap$54M
5Y Perf.-98.4%
TMO
Thermo Fisher Scientific Inc.

Medical - Diagnostics & Research

HealthcareNYSE • US
Market Cap$174.42B
5Y Perf.+2.8%
ILMN
Illumina, Inc.

Medical - Diagnostics & Research

HealthcareNASDAQ • US
Market Cap$24.45B
5Y Perf.-56.9%
DHR
Danaher Corporation

Medical - Diagnostics & Research

HealthcareNYSE • US
Market Cap$127.47B
5Y Perf.-9.7%
A
Agilent Technologies, Inc.

Medical - Diagnostics & Research

HealthcareNYSE • US
Market Cap$36.67B
5Y Perf.+2.1%
KO
The Coca-Cola Company

Beverages - Non-Alcoholic

Consumer DefensiveNYSE • US
Market Cap$355.61B
5Y Perf.+56.7%
JPM
JPMorgan Chase & Co.

Banks - Diversified

Financial ServicesNYSE • US
Market Cap$896.00B
5Y Perf.+110.7%

TIL vs TMO vs ILMN vs DHR vs A vs KO vs JPM — Key Financials

Market cap, revenue, margins, and valuation side-by-side.

Company Snapshot
TIL logoTIL
TMO logoTMO
ILMN logoILMN
DHR logoDHR
A logoA
KO logoKO
JPM logoJPM
IndustryBiotechnologyMedical - Diagnostics & ResearchMedical - Diagnostics & ResearchMedical - Diagnostics & ResearchMedical - Diagnostics & ResearchBeverages - Non-AlcoholicBanks - Diversified
Market Cap$54M$174.42B$24.45B$127.47B$36.67B$355.61B$896.00B
Revenue (TTM)$0.00$45.20B$4.39B$24.78B$7.23B$49.28B$280.33B
Net Income (TTM)$-47M$6.86B$853M$3.69B$1.41B$13.70B$57.05B
Gross Margin39.4%67.1%60.7%53.0%61.7%60.0%
Operating Margin17.8%20.9%21.0%21.5%29.3%25.9%
Forward P/E18.9x30.8x21.3x21.4x25.3x14.4x
Total Debt$85M$40.85B$2.55B$18.42B$3.35B$45.49B$942.38B
Cash & Equiv.$7M$9.86B$1.42B$4.62B$1.79B$10.27B$343.34B

TIL vs TMO vs ILMN vs DHR vs A vs KO vs JPMLong-Term Stock Performance

Price return indexed to 100 at period start. Dividends excluded.

TIL
TMO
ILMN
DHR
A
KO
JPM
StockMar 21Jun 26Return
Instil Bio, Inc. (TIL)1001.6-98.4%
Thermo Fisher Scien… (TMO)100102.8+2.8%
Illumina, Inc. (ILMN)10043.1-56.9%
Danaher Corporation (DHR)10090.3-9.7%
Agilent Technologie… (A)100102.1+2.1%
The Coca-Cola Compa… (KO)100156.7+56.7%
JPMorgan Chase & Co. (JPM)100210.7+110.7%

Price return only. Dividends and distributions are not included.

Quick Verdict: TIL vs TMO vs ILMN vs DHR vs A vs KO vs JPM

Each card shows where this stock fits in a portfolio — not just who wins on paper.

Bottom line: ILMN and KO are tied at the top with 2 categories each (7-stock set) — the right choice depends on your priorities. The Coca-Cola Company is the stronger pick specifically for profitability and margin quality and dividend income and shareholder returns. TIL, DHR, and JPM also each lead in at least one category. This set spans 3 sectors — these stocks serve different portfolio roles, not just different price points.
TIL
Instil Bio, Inc.
The Growth Leader

TIL ranks third and is worth considering specifically for growth.

  • 37.2% revenue growth vs ILMN's -0.8%
Best for: growth
TMO
Thermo Fisher Scientific Inc.
The Healthcare Pick

TMO doesn't hold a clear category lead here; it's more of a secondary option in this specific comparison.

Best for: healthcare exposure
ILMN
Illumina, Inc.
The Momentum Pick

ILMN has the current edge in this matchup, primarily because of its strength in momentum and efficiency.

  • +82.7% vs TIL's -78.9%
  • 13.4% ROA vs TIL's -22.4%, ROIC 16.8% vs -18.0%
Best for: momentum and efficiency
DHR
Danaher Corporation
The Defensive Pick

DHR is the clearest fit if your priority is sleep-well-at-night and defensive.

  • Lower volatility, beta 0.70, Low D/E 35.1%, current ratio 1.87x
  • Beta 0.70, yield 0.7%, current ratio 1.87x
  • Beta 0.70 vs TIL's 1.55, lower leverage
Best for: sleep-well-at-night and defensive
A
Agilent Technologies, Inc.
The Growth Play

A is the clearest fit if your priority is growth exposure.

  • Rev growth 6.7%, EPS growth 3.2%, 3Y rev CAGR 0.5%
Best for: growth exposure
KO
The Coca-Cola Company
The Quality Compounder

KO is the #2 pick in this set and the best alternative if quality and dividends is your priority.

  • 27.8% margin vs TIL's -1.0%
  • 2.5% yield, 56-year raise streak, vs DHR's 0.7%, (2 stocks pay no dividend)
Best for: quality and dividends
JPM
JPMorgan Chase & Co.
The Banking Pick

JPM is the clearest fit if your priority is income & stability and long-term compounding.

  • Dividend streak 15 yrs, beta 0.94, yield 1.9%
  • 465.8% 10Y total return vs TMO's 219.0%
  • PEG 0.81 vs DHR's 35.21
  • Lower P/E (14.4x vs 25.3x), PEG 0.81 vs 2.26
Best for: income & stability and long-term compounding
See the full category breakdown
CategoryWinnerWhy
GrowthTIL logoTIL37.2% revenue growth vs ILMN's -0.8%
ValueJPM logoJPMLower P/E (14.4x vs 25.3x), PEG 0.81 vs 2.26
Quality / MarginsKO logoKO27.8% margin vs TIL's -1.0%
Stability / SafetyDHR logoDHRBeta 0.70 vs TIL's 1.55, lower leverage
DividendsKO logoKO2.5% yield, 56-year raise streak, vs DHR's 0.7%, (2 stocks pay no dividend)
Momentum (1Y)ILMN logoILMN+82.7% vs TIL's -78.9%
Efficiency (ROA)ILMN logoILMN13.4% ROA vs TIL's -22.4%, ROIC 16.8% vs -18.0%

TIL vs TMO vs ILMN vs DHR vs A vs KO vs JPM — Revenue Breakdown by Segment

How each company's revenue is distributed across its business units

Discover the Biotech & Healthcare Stocks Theme

These companies are key players in the Biotech & Healthcare Stocks ecosystem. See how they stack up against the rest of the sector.

Explore Theme
TILInstil Bio, Inc.

Segment breakdown not available.

TMOThermo Fisher Scientific Inc.
FY 2025
Consumables
41.9%$18.7B
Service
41.7%$18.6B
Instruments
16.4%$7.3B
ILMNIllumina, Inc.
FY 2025
Sequencing
91.8%$4.0B
Microarray
8.2%$358M
DHRDanaher Corporation
FY 2025
Revenue from Contract with Customer, Measurement, Recurring
81.9%$20.1B
Revenue from Contract with Customer, Measurement, Nonrecurring
18.1%$4.4B
AAgilent Technologies, Inc.
FY 2025
Agilent CrossLab
41.9%$2.9B
Life Sciences and Applied Markets
39.2%$2.7B
Applied Markets
18.9%$1.3B
KOThe Coca-Cola Company
FY 2025
Pacific
84.6%$31.6B
Bottling investments
15.4%$5.7B
JPMJPMorgan Chase & Co.
FY 2025
Commercial And Investment Bank
43.0%$78.5B
Consumer & Community Banking
41.7%$76.0B
Asset and Wealth Management Segment
13.2%$24.1B
Segment Reporting, Reconciling Item, Corporate Nonsegment
3.9%$7.0B
Segment Reconciling Items
-1.7%$-3,134,000,000

TIL vs TMO vs ILMN vs DHR vs A vs KO vs JPM — Financial Metrics

Side-by-side numbers across 7 stocks — who leads on profitability, valuation, growth, and risk.

BEST OVERALLKOLAGGINGA

Income & Cash Flow (Last 12 Months)

KO leads this category, winning 3 of 6 comparable metrics.

JPM and TIL operate at a comparable scale, with $280.3B and $0 in trailing revenue. KO is the more profitable business, keeping 27.8% of every revenue dollar as net income compared to DHR's 14.9%. On growth, KO holds the edge at +12.1% YoY revenue growth, suggesting stronger near-term business momentum.

MetricTIL logoTILInstil Bio, Inc.TMO logoTMOThermo Fisher Sci…ILMN logoILMNIllumina, Inc.DHR logoDHRDanaher Corporati…A logoAAgilent Technolog…KO logoKOThe Coca-Cola Com…JPM logoJPMJPMorgan Chase & …
RevenueTrailing 12 months$0$45.2B$4.4B$24.8B$7.2B$49.3B$280.3B
EBITDAEarnings before interest/tax-$54M$10.5B$1.1B$7.2B$1.8B$15.5B$81.4B
Net IncomeAfter-tax profit-$47M$6.9B$853M$3.7B$1.4B$13.7B$57.0B
Free Cash FlowCash after capex-$34M$6.7B$989M$5.3B$1.3B$12.6B$100.9B
Gross MarginGross profit ÷ Revenue+39.4%+67.1%+60.7%+53.0%+61.7%+60.0%
Operating MarginEBIT ÷ Revenue+17.8%+20.9%+21.0%+21.5%+29.3%+25.9%
Net MarginNet income ÷ Revenue+15.2%+19.4%+14.9%+19.6%+27.8%+20.4%
FCF MarginFCF ÷ Revenue+14.9%+22.5%+21.4%+17.4%+25.5%+36.0%
Rev. Growth (YoY)Latest quarter vs prior year+6.2%+4.8%+3.7%+10.0%+12.1%
EPS Growth (YoY)Latest quarter vs prior year+85.6%+11.3%+6.1%+9.8%+60.0%+18.2%+16.0%
KO leads this category, winning 3 of 6 comparable metrics.

Valuation Metrics

JPM leads this category, winning 5 of 7 comparable metrics.

At 16.0x trailing earnings, JPM trades at a 55% valuation discount to DHR's 35.7x P/E. Adjusting for growth (PEG ratio), JPM offers better value at 0.90x vs DHR's 35.21x — a lower PEG means you pay less per unit of expected earnings growth.

MetricTIL logoTILInstil Bio, Inc.TMO logoTMOThermo Fisher Sci…ILMN logoILMNIllumina, Inc.DHR logoDHRDanaher Corporati…A logoAAgilent Technolog…KO logoKOThe Coca-Cola Com…JPM logoJPMJPMorgan Chase & …
Market CapShares × price$54M$174.4B$24.5B$127.5B$36.7B$355.6B$896.0B
Enterprise ValueMkt cap + debt − cash$132M$205.4B$25.6B$141.3B$38.2B$390.8B$1.50T
Trailing P/EPrice ÷ TTM EPS-0.74x26.46x29.54x35.73x28.41x27.18x16.00x
Forward P/EPrice ÷ next-FY EPS est.18.88x30.83x21.34x21.43x25.27x14.40x
PEG RatioP/E ÷ EPS growth rate12.53x6.98x35.21x1.93x2.43x0.90x
EV / EBITDAEnterprise value multiple18.86x22.56x18.63x21.64x26.39x18.36x
Price / SalesMarket cap ÷ Revenue3.91x5.64x5.19x5.28x7.42x3.20x
Price / BookPrice ÷ Book value/share0.46x3.31x9.22x2.44x5.47x10.40x2.47x
Price / FCFMarket cap ÷ FCF27.72x26.26x24.23x31.83x67.15x8.88x
JPM leads this category, winning 5 of 7 comparable metrics.

Profitability & Efficiency

ILMN leads this category, winning 4 of 9 comparable metrics.

KO delivers a 41.1% return on equity — every $100 of shareholder capital generates $41 in annual profit, vs $-40 for TIL. DHR carries lower financial leverage with a 0.35x debt-to-equity ratio, signaling a more conservative balance sheet compared to JPM's 2.60x. On the Piotroski fundamental quality scale (0–9), ILMN scores 8/9 vs TIL's 2/9, reflecting strong financial health.

MetricTIL logoTILInstil Bio, Inc.TMO logoTMOThermo Fisher Sci…ILMN logoILMNIllumina, Inc.DHR logoDHRDanaher Corporati…A logoAAgilent Technolog…KO logoKOThe Coca-Cola Com…JPM logoJPMJPMorgan Chase & …
ROE (TTM)Return on equity-39.8%+13.2%+32.8%+7.1%+20.8%+41.1%+15.9%
ROA (TTM)Return on assets-22.4%+6.4%+13.4%+4.5%+11.1%+13.1%+1.3%
ROICReturn on invested capital-18.0%+7.5%+16.8%+5.9%+13.5%+15.8%+4.5%
ROCEReturn on capital employed-23.3%+9.1%+17.6%+7.0%+14.5%+17.3%+8.9%
Piotroski ScoreFundamental quality 0–92687575
Debt / EquityFinancial leverage0.75x0.76x0.94x0.35x0.50x1.33x2.60x
Net DebtTotal debt minus cash$79M$31.0B$1.1B$13.8B$1.6B$35.2B$599.0B
Cash & Equiv.Liquid assets$7M$9.9B$1.4B$4.6B$1.8B$10.3B$343.3B
Total DebtShort + long-term debt$85M$40.9B$2.6B$18.4B$3.4B$45.5B$942.4B
Interest CoverageEBIT ÷ Interest expense-8.24x5.89x12.09x18.13x15.72x10.70x0.74x
ILMN leads this category, winning 4 of 9 comparable metrics.

Total Returns (Dividends Reinvested)

JPM leads this category, winning 4 of 6 comparable metrics.

A $10,000 investment in JPM five years ago would be worth $21,820 today (with dividends reinvested), compared to $239 for TIL. Over the past 12 months, ILMN leads with a +82.7% total return vs TIL's -78.9%. The 3-year compound annual growth rate (CAGR) favors JPM at 33.6% vs TIL's -11.1% — a key indicator of consistent wealth creation.

MetricTIL logoTILInstil Bio, Inc.TMO logoTMOThermo Fisher Sci…ILMN logoILMNIllumina, Inc.DHR logoDHRDanaher Corporati…A logoAAgilent Technolog…KO logoKOThe Coca-Cola Com…JPM logoJPMJPMorgan Chase & …
YTD ReturnYear-to-date-29.7%-20.7%+19.8%-21.7%-5.5%+20.3%-0.5%
1-Year ReturnPast 12 months-78.9%+13.4%+82.7%-11.5%+10.0%+17.2%+21.8%
3-Year ReturnCumulative with dividends-29.8%-9.5%-20.4%-13.0%+12.0%+47.0%+138.2%
5-Year ReturnCumulative with dividends-97.6%+1.4%-63.4%-15.5%-6.9%+65.6%+118.2%
10-Year ReturnCumulative with dividends-98.5%+219.0%+18.6%+222.6%+206.2%+121.1%+465.8%
CAGR (3Y)Annualised 3-year return-11.1%-3.3%-7.3%-4.5%+3.8%+13.7%+33.6%
JPM leads this category, winning 4 of 6 comparable metrics.

Risk & Volatility

KO leads this category, winning 2 of 2 comparable metrics.

KO is the less volatile stock with a -0.20 beta — it tends to amplify market swings less than TIL's 1.55 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. KO currently trades 98.3% from its 52-week high vs TIL's 20.6% drawdown — a narrower gap to the peak suggests stronger recent price momentum.

MetricTIL logoTILInstil Bio, Inc.TMO logoTMOThermo Fisher Sci…ILMN logoILMNIllumina, Inc.DHR logoDHRDanaher Corporati…A logoAAgilent Technolog…KO logoKOThe Coca-Cola Com…JPM logoJPMJPMorgan Chase & …
Beta (5Y)Sensitivity to S&P 5001.55x0.91x0.99x0.70x1.06x-0.20x0.94x
52-Week HighHighest price in past year$38.50$643.99$177.22$242.80$160.27$84.04$337.25
52-Week LowLowest price in past year$5.67$385.46$85.77$160.93$108.35$65.35$262.71
% of 52W HighCurrent price vs 52-week peak+20.6%+72.9%+90.8%+74.2%+81.0%+98.3%+95.1%
RSI (14)Momentum oscillator 0–10040.950.866.452.056.160.659.1
Avg Volume (50D)Average daily shares traded26K2.0M1.7M4.2M1.9M12.7M7.0M
KO leads this category, winning 2 of 2 comparable metrics.

Analyst Outlook

KO leads this category, winning 2 of 2 comparable metrics.

Analyst consensus: TMO as "Buy", ILMN as "Buy", DHR as "Buy", A as "Buy", KO as "Buy", JPM as "Buy". Consensus price targets imply 28.7% upside for DHR (target: $232) vs -5.9% for ILMN (target: $151). For income investors, KO offers the higher dividend yield at 2.46% vs TMO's 0.36%.

MetricTIL logoTILInstil Bio, Inc.TMO logoTMOThermo Fisher Sci…ILMN logoILMNIllumina, Inc.DHR logoDHRDanaher Corporati…A logoAAgilent Technolog…KO logoKOThe Coca-Cola Com…JPM logoJPMJPMorgan Chase & …
Analyst RatingConsensus buy/hold/sellBuyBuyBuyBuyBuyBuy
Price TargetConsensus 12-month target$599.70$151.40$231.80$154.75$86.13$339.75
# AnalystsCovering analysts425043404861
Dividend YieldAnnual dividend ÷ price+0.4%+0.7%+0.8%+2.5%+1.9%
Dividend StreakConsecutive years of raises8905615
Dividend / ShareAnnual DPS$1.69$1.23$0.99$2.04$5.95
Buyback YieldShare repurchases ÷ mkt cap0.0%+1.7%+3.0%+2.4%+1.2%+0.2%+3.9%
KO leads this category, winning 2 of 2 comparable metrics.
Key Takeaway

KO leads in 3 of 6 categories (Income & Cash Flow, Risk & Volatility). JPM leads in 2 (Valuation Metrics, Total Returns).

Best OverallThe Coca-Cola Company (KO)Leads 3 of 6 categories
Loading custom metrics...

TIL vs TMO vs ILMN vs DHR vs A vs KO vs JPM: Key Questions Answered

10 questions · data-driven answers · updated daily

01

Is TIL or TMO or ILMN or DHR or A or KO or JPM a better buy right now?

For growth investors, Agilent Technologies, Inc.

(A) is the stronger pick with 6. 7% revenue growth year-over-year, versus -0. 8% for Illumina, Inc. (ILMN). JPMorgan Chase & Co. (JPM) offers the better valuation at 16. 0x trailing P/E (14. 4x forward), making it the more compelling value choice. Analysts rate Thermo Fisher Scientific Inc. (TMO) a "Buy" — based on 42 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

02

Which has the better valuation — TIL or TMO or ILMN or DHR or A or KO or JPM?

On trailing P/E, JPMorgan Chase & Co.

(JPM) is the cheapest at 16. 0x versus Danaher Corporation at 35. 7x. On forward P/E, JPMorgan Chase & Co. is actually cheaper at 14. 4x. The PEG ratio (P/E divided by earnings growth rate) is the most growth-adjusted single valuation metric: JPMorgan Chase & Co. wins at 0. 81x versus Danaher Corporation's 35. 21x — a PEG below 1. 0 traditionally signals the market is underpricing earnings growth.

03

Which is the better long-term investment — TIL or TMO or ILMN or DHR or A or KO or JPM?

Over the past 5 years, JPMorgan Chase & Co.

(JPM) delivered a total return of +118. 2%, compared to -97. 6% for Instil Bio, Inc. (TIL). Over 10 years, the gap is even starker: JPM returned +465. 8% versus TIL's -98. 5%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

04

Which is safer — TIL or TMO or ILMN or DHR or A or KO or JPM?

By beta (market sensitivity over 5 years), The Coca-Cola Company (KO) is the lower-risk stock at -0.

20β versus Instil Bio, Inc. 's 1. 55β — meaning TIL is approximately -876% more volatile than KO relative to the S&P 500. On balance sheet safety, Danaher Corporation (DHR) carries a lower debt/equity ratio of 35% versus 3% for JPMorgan Chase & Co. — giving it more financial flexibility in a downturn.

05

Which is growing faster — TIL or TMO or ILMN or DHR or A or KO or JPM?

By revenue growth (latest reported year), Agilent Technologies, Inc.

(A) is pulling ahead at 6. 7% versus -0. 8% for Illumina, Inc. (ILMN). On earnings-per-share growth, the picture is similar: Illumina, Inc. grew EPS 170. 9% year-over-year, compared to -4. 7% for Danaher Corporation. Over a 3-year CAGR, KO leads at 3. 7% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

06

Which has better profit margins — TIL or TMO or ILMN or DHR or A or KO or JPM?

The Coca-Cola Company (KO) is the more profitable company, earning 27.

3% net margin versus 0. 0% for Instil Bio, Inc. — meaning it keeps 27. 3% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: KO leads at 28. 7% versus 0. 0% for TIL. At the gross margin level — before operating expenses — ILMN leads at 66. 7%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

07

Is TIL or TMO or ILMN or DHR or A or KO or JPM more undervalued right now?

The PEG ratio (forward P/E divided by expected earnings growth rate) is the most precise measure of undervaluation relative to growth potential.

By this metric, JPMorgan Chase & Co. (JPM) is the more undervalued stock at a PEG of 0. 81x versus Danaher Corporation's 35. 21x. A PEG below 1. 0 is traditionally considered the threshold for growth-adjusted undervaluation. On forward earnings alone, JPMorgan Chase & Co. (JPM) trades at 14. 4x forward P/E versus 30. 8x for Illumina, Inc. — 16. 4x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for DHR: 28. 7% to $231. 80.

08

Which pays a better dividend — TIL or TMO or ILMN or DHR or A or KO or JPM?

In this comparison, KO (2.

5% yield), JPM (1. 9% yield), A (0. 8% yield), DHR (0. 7% yield), TMO (0. 4% yield) pay a dividend. TIL, ILMN do not pay a meaningful dividend and should not be held primarily for income.

09

Is TIL or TMO or ILMN or DHR or A or KO or JPM better for a retirement portfolio?

For long-horizon retirement investors, The Coca-Cola Company (KO) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β -0.

20), 2. 5% yield, +121. 1% 10Y return). Instil Bio, Inc. (TIL) carries a higher beta of 1. 55 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (KO: +121. 1%, TIL: -98. 5%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

10

What are the main differences between TIL and TMO and ILMN and DHR and A and KO and JPM?

These companies operate in different sectors (TIL (Healthcare) and TMO (Healthcare) and ILMN (Healthcare) and DHR (Healthcare) and A (Healthcare) and KO (Consumer Defensive) and JPM (Financial Services)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.

In terms of investment character: TIL is a small-cap quality compounder stock; TMO is a mid-cap quality compounder stock; ILMN is a mid-cap quality compounder stock; DHR is a mid-cap quality compounder stock; A is a mid-cap quality compounder stock; KO is a large-cap quality compounder stock; JPM is a large-cap deep-value stock. DHR, A, KO, JPM pay a dividend while TIL, TMO, ILMN do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.

You Might Also Compare

Based on how these companies actually compete and overlap — not just which sector they're filed under.